[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100390055":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":46,"collaborators":20,"id":48,"slug":20,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":20,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"AHS Cancer Control Alberta","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MR Imaging on the Alberta linac-MR P3 system","EXPERIMENTAL","All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.",[13],"Device: MR scan with the Alberta linac-MR P3 system",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","MR scan with the Alberta linac-MR P3 system","Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Nawaid Usmani, MD","Cross Cancer Institute, Alberta Health Services","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","780-432-8518","Nawaid.Usmani@ahs.ca",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":20},"Cross Cancer Institute","RECRUITING","Edmonton","Alberta","T6G 1Z2","Canada","CA",{"type":41,"coordinates":42},"Point",[43,44],-113.46871,53.55014,{"lat":44,"lon":43},{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100390055",false,"NCT04358913","MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)","Northern Alberta Linac-MR Image-Guided Human Clinical Trials - 1","Inclusion Criteria:\n\n* Adults ≥ 18 years of age\n* Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist\n\nExclusion Criteria:\n\n* Patients with contraindications for MRI\n* Patients who are unable to lie flat and still for the duration of the expected scan acquisition\n* Patients who are unable to provide informed consent","ALL","18 Years",{"count":57,"type":58},250,"ESTIMATED","INTERVENTIONAL",[61],"NA","Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). The purpose of this pilot phase of the study is to test whether the Alberta linac-MR P3 system at the Cross Cancer Institute can acquire high quality MR images safely. It will allow the researchers to develop the best collection of MR images possible with this new machine, in order to allow them to visualize tumors for future patients that are treated on this machine.",[64],"Cancer","2025-05-09",{"date":67,"type":68},"2025-05-14","ACTUAL",{"date":70,"type":68},"2021-08-23",{"date":72,"type":58},"2029-01",{"name":5,"class":6},1]